NRAS is a member of the RAS family of oncogenes. Activating point mutations in NRAS gene have been reported in a wide variety of tumors and they mostly concentrate in codons 12, 13 and codon 61. Activating mutations in NRAS are rare in pancreatic ductal adenocarcinomas (PDAC). The predictive and prognostic significance of NRAS mutations in PDAC is unclear and needs to be further studied. Correlation with other clinical and laboratory findings is recommended.